ATON 0.006 € (-6,06 %) AYVENS 9.090 € (+0,72 %) VIRIDIEN 97.150 € (+5,94 %) STIF 19.000 € (-3,41 %) EXOSENS 54.250 € (-2,16 %) EMEIS 10.050 € (+1,41 %) 
CVC CAPITAL 14.300 € (+0,21 %) LIGHTON 1.300 € (+1,56 %) FDJ UNITED 21.670 € (-0,28 %) BOUYGUES 41.430 € (+0,97 %) LVMH 401.700 € (+0,05 %) CREDIT AGRICOLE 15.315 € (+1,96 %) TOTALENERGIES 83.320 € (+0,74 %) CHRISTIAN DIOR 435.800 € (+0,14 %) EUROFINS SCIENT. 87.000 € (-0,28 %) ADOCIA 2.896 € (-1,16 %) KERING 183.240 € (+1,66 %) NANOBIOTIX 26.420 € (+3,45 %) HERMES INTL 1 312.500 € (0,00 %) SANOFI 81.140 € (+0,20 %) BE SEMICONDUCTOR 157.900 € (+1,15 %) 
GALP ENERGIA-NOM 20.010 € (0,00 %) SOCIETE GENERALE 63.680 € (+3,46 %) L'OREAL 431.500 € (-0,28 %) AVANTIUM 2.355 € (+0,64 %) WOLTERS KLUWER 85.240 € (-0,23 %) AIR LIQUIDE 182.780 € (+0,12 %) ADYEN 837.000 € (+1,11 %) PROSUS 35.660 € (+1,11 %) ENGIE 23.620 € (+1,29 %) 
AEGON 7.536 € (+1,56 %) ARTMARKET COM 3.230 € (-0,31 %) VOPAK 55.300 € (+4,05 %) GTT 188.700 € (+0,75 %) ING GROEP N.V. 28.530 € (+2,94 %) B.COM.PORTUGUES 1.048 € (0,00 %) ACCOR 48.070 € (+0,52 %) FRANCAISE ENERGIE 18.140 € (-1,84 %) KPN KON 4.327 € (+0,14 %) BNP PARIBAS ACT.A 89.720 € (+2,41 %) PHARMING GROUP 1.141 € (+0,62 %) 
ARCELORMITTAL SA 55.420 € (+2,33 %) AXA 43.510 € (+1,07 %) WORLDLINE 10.680 € (-0,43 %) DANONE 65.860 € (-0,24 %) AHOLD DEL 33.090 € (+2,89 %) ALSTOM 11.080 € (-0,40 %) SCHNEIDER ELECTRIC 241.450 € (+0,71 %) 
SHELL PLC 46.660 € (+0,31 %) ASR NEDERLAND 76.900 € (+1,02 %) ABN AMRO BANK N.V. 40.810 € (+2,62 %) 2CRSI 17.520 € (+5,61 %) SAINT GOBAIN 71.180 € (+1,22 %) THALES 224.200 € (-3,78 %) CBI 0.111 € (+6,56 %) ASML HOLDING 1 399.400 € (+1,04 %) ARKEMA 56.700 € (+0,35 %) 
DSM FIRMENICH AG 99.760 € (-5,58 %) SPIE 44.720 € (-0,18 %) CAPGEMINI 123.800 € (-1,12 %) |
13/10/2026 22:37
EQS-Adhoc: Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidanceEQS-Ad-hoc: Evotec SE / Key word(s): Forecast / Other Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance Hamburg, Germany – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for first nine months of 2026. Full financial results for the third quarter and the first nine months of 2026 will be published on November 5, 2026, as scheduled. Based on preliminary figures, Evotec expects Group revenues for the first nine months of 2026 of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million. These figures are above current market expectations, with the variance driven largely by the phasing of consensus estimates. Evotec reaffirms its full-year 2026 guidance, which projects Group revenues of approximately €570 to €610 million (€595 to €635 million at CER) and adjusted Group EBITDA of approximately -€70 to -€105 million (-€60 to -€90 million at CER). – End of the ad hoc release – Contact: Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 7068 8784 (m), sarah.fakih@evotec.com End of Inside Information 13-Oct-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
2415242 13-Oct-2026 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||||||||||||||||||
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière